ExchangeDEX+

Buy Crypto Markets Spot FuturesBTC Earn Event Center

DUBLIN–(BUSINESS WIRE)–The “Advanced Pharmacovigilance: From Performing Successful Due Diligence to Benefit-Risk Assessments – What to Consider Training Course (DUBLIN–(BUSINESS WIRE)–The “Advanced Pharmacovigilance: From Performing Successful Due Diligence to Benefit-Risk Assessments – What to Consider Training Course (

Advanced Pharmacovigilance Training Course: Performing Successful Due Diligence to Benefit-Risk Assessments and What to Consider (Online Event: Mar 23rd – Mar 25th, 2026) – ResearchAndMarkets.com

Author: AI Journal

Source: AI Journal

2025/12/30 00:31

DUBLIN–(BUSINESS WIRE)–The “Advanced Pharmacovigilance: From Performing Successful Due Diligence to Benefit-Risk Assessments – What to Consider Training Course (Mar 23rd – Mar 25th, 2026)” training has been added to ResearchAndMarkets.com’s offering.

This course is designed for those with at least two years’ knowledge in drug safety and will provide a comprehensive, yet practical assessment of the main regulations required to produce a compliant reporting company. Pharmacovigilance has undergone rapid regulatory change in recent years, which has resulted in a complex range of safety and risk assessment activities to perform.

Who Should Attend:

This course would be of maximum benefit to those safety professionals who are working both in the clinical and post-marketing safety arena including QA for auditing. The course covers very diverse activities within the safety department and would be advantageous to those who have either multifunction responsibilities or medical directors who manage teams in the various disciplines.

Key topics to be addressed:

Audits and expectations – risk-based inspections
Compliance and drug safety
Overview of the PSMF in the EU
Product safety reviews – purpose and function (incorporating the latest EU signal analysis requirements)
Safety reporting in licensing agreements
Developing company core safety information (CCSI) – CIOMS III
PSURs – timing, content and the DSUR and the latest ICH E2C (2nd revision requirements)
Implications for safety reporting in global clinical trials
Risk-benefit determinations
Risk management plans (RMPs)

Benefits of attending

Expand your global safety knowledge
Enhance your team’s capabilities and compliance in both the regulations and your company’s expectations
Help ensure you build and maintain a quality pharmacovigilance department ready for any pharmacovigilance inspection
Participate in group workshop sessions and discuss how to apply the legislation to ensure compliance, especially to satisfy regulatory inspections

Certifications:

CPD: 18 hours for your records
Certificate of completion

Key Topics Covered:

Due diligence

Due diligence on products/companies (partners and acquisitions)
Due diligence involvement – team composition
Safety information requirements for due diligence
Review of safety data (clinical and post-marketing)
Defining risk in due diligence appraisals

Training for drug safety reporting duties

Regulations concerning safety training
Who trains whom and when?
Training versus job description
Training records, maintenance and updates
Role of QA and HR in training

Audits and expectations

Regulatory expectations in pharmacovigilance audits (risk-based inspections)
Preparation for the audit
Records to be available at the audit
Audit findings/recommendations

Compliance and drug safety

Basic principles – what will the regulators want to see?
Measuring compliance
Quality versus quantity in safety reports
Future aspects in ensuring efficient compliance
Quality management under the new EU legislation

The PSMF

The PSMF – purpose and maintenance
The PSMF annexes
The PSMF and audits

Interactive exercise: The requirements for a safety department

Product safety reviews – purpose and function

The Safety Review Committee (SRC)
What to look for in signal evaluation under latest EU guidance
Timings for safety review in clinical and post-marketed products
Record keeping for safety review meetings
Serious safety findings – crisis management following new safety findings

Interactive exercise: designing the requirements for a safety review group

Safety reporting in licensing agreements

What types of licensing agreements exist?
What are the EU and FDA regulations concerning licensing agreements?
Audits of pharmacovigilance capabilities in licensing partners
What agreements need to be in place for safety reporting?
Safety reporting agreements – what needs to be covered?
Monitoring safety agreements – what happens if it goes wrong?

Developing CCSI – CIOMS III

CIOMS III and CCSI
Developmental core safety information (DCSI)
How to determine what to include and what to exclude in DCSI/CCSI
Are there differences in EU and FDA?
Maintenance and development of CCSI

Interactive exercise: should new safety data from a clinical trial be put into core safety information?

PSURs and the revisions in ICH E2C

Timing for PSURs
PSUR content and latest format
Late breaking information and PSUR extensions
The DSUR

The EU Clinical Trials Directive

The principles of the Directive
Implications for safety reporting in global clinical trials
The SUSAR database
The EUDRACT database
The new EU clinical trial regulation

Risk-benefit determinations

Definitions of risk-benefit – FDA and EU perspective
Risk-benefit assessments – who does this and where does the information go?
Safety assessments and risk-benefit – frequency and reporting
Changes in risk-benefit – how to manage and review existing profiles

Risk-benefit determinations

Definitions of risk-benefit – FDA and EU perspective
Risk-benefit assessments – who does this and where does the information go?
Safety assessments and risk-benefit – frequency and reporting
Changes in risk-benefit – how to manage and review existing profiles

Interactive exercise: reviewing the safety and risk-benefit of a product

RMPs

Purpose
Content
Monitoring and updating the RMP
Reporting the RMP

Crisis management within drug safety

Regulations and guidelines in connection with serious safety issues
What determines a crisis?
Communications to regulators – what is required?
Communications within the company
What happens next?

Interactive exercise: deciding how to handle a major crisis within the company

Delegates will be split into groups and present what they need to have in place in order to effectively manage the crisis and look to its resolution.

Speakers:

Graeme Ladds

Director

PharSafer Associates Ltd.

Graeme Ladds, Director of PharSafer, has over 30 years’ experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals.

He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.

For more information about this training visit https://www.researchandmarkets.com/r/v06j3e

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.